Cost-Effectiveness Analysis of Six Immunotherapy-Based Regimens and Sunitinib in Metastatic Renal Cell Carcinoma: A Public Payer Perspective

Several new treatment combinations have been approved in metastatic renal cell carcinoma (mRCC). To determine the optimal therapy on the basis of cost and health outcomes, we performed a cost-effectiveness analysis of approved immunotherapy-tyrosine kinase inhibitor/immunotherapy drug combinations a...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoo, Minkyoung, Nelson, Richard E., Cutshall, Zachary, Dougherty, Maura, Kohli, Manish
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2023
Materias:
ORIGINAL CONTRIBUTIONS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10022876/
https://www.ncbi.nlm.nih.gov/pubmed/36599117
http://dx.doi.org/10.1200/OP.22.00447

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10022876/
https://www.ncbi.nlm.nih.gov/pubmed/36599117
http://dx.doi.org/10.1200/OP.22.00447

Ejemplares similares